Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial
Bedeutung niedrig- und mittelgradiger unerwünschter Ereignisse für das Behandlungserleben und den Therapieabbruch: Analyse der E1912-Studie
Journal of Clinical Oncology · 20.01.2024 · 42 (3) · 266-272
DOI: 10.1200/jco.23.00377 ↗Auf einen Blick
In einer Phase-III-Analyse waren G1- und G2-Nebenwirkungen mit stärkerem Behandlungsside-effect-Bother assoziiert. G2-Ereignisse erhöhten zudem die Wahrscheinlichkeit eines Therapieabbruchs.
Fragestellung
Wie hängen G1- und G2-Unerwünschte Ereignisse mit dem berichteten Belastungserleben durch Nebenwirkungen und mit Therapieabbrüchen zusammen?
Methode
Analyse einer Phase-III-Studie mit vollständigen AE-Daten; Bayesianische gemischte Modelle; Bewertung von G1- und G2-AE-Zahlen sowie symptomatischen und asymptomatischen AEs.
Ergebnisse
Jedes zusätzliche G1-AE pro Behandlungszyklus erhöhte die Odds für mehr Bother um 13 % (95 % CrI 1.06–1.21), jedes G2-AE um 35 % (95 % CrI 1.19–1.54). G2-AEs erhöhten die Odds für Abbruch um 59 % (95 % CrI 1.32–1.95).
Schlussfolgerung der Autor:innen
Niedrig- und mittelgradige AEs waren mit höherer Belastung durch Nebenwirkungen und mit Therapieabbrüchen verbunden; symptomatische AEs zeigten stärkere Assoziationen als asymptomatische.
Kernaussagen
- G1-AEs und G2-AEs erhöhten die berichtete Nebenwirkungsbelastung.
- Nur symptomatische AEs waren mit mehr Bother assoziiert.
- G2-AEs waren mit Therapieabbrüchen assoziiert.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2024. Verfasst von Nathaniel S O'Connell und 15 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest University School of Medicine, Winston-Salem, NC. Hauptthemen laut MEDLINE: Bayes Theorem. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Themen: Patientensicherheit
Abstract (Originalsprache)
PURPOSE Despite defined grades of 1 to 5 for adverse events (AEs) on the basis of Common Terminology Criteria for Adverse Events criteria, mild (G1) and moderate (G2) AEs are often not reported in phase III trials. This under-reporting may inhibit our ability to understand patient toxicity burden. We analyze the relationship between the grades of AEs experienced with patient side-effect bother and treatment discontinuation . METHODS We analyzed a phase III Eastern Cooperative Oncology Group-American College of Radiology Imaging Network trial with comprehensive AE data. The Likert response Functional Assessment of Cancer Therapy-GP5 item, “I am bothered by side effects of treatment” was used to define side-effect bother. Bayesian mixed models were used to assess the impact of G1 and G2 AE counts on patient side-effect bother and treatment discontinuation. AEs were further analyzed on the basis of symptomatology (symptomatic or asymptomatic). The results are given as odds ratios (ORs) and 95% credible interval (CrI). RESULTS Each additional G1 and G2 AEs experienced during a treatment cycle increased the odds of increased self-reported patient side-effect bother by 13% (95% CrI, 1.06 to 1.21) and 35% (95% CrI, 1.19 to 1.54), respectively. Furthermore, only AEs defined as symptomatic were associated with increased side-effect bother, with asymptomatic AEs showing no association regardless of grade. Count of G2 AEs increased the odds of treatment discontinuation by 59% (95% CrI, 1.32 to 1.95), with symptomatic G2 AEs showing a stronger association (OR, 1.75; 95% CrI, 1.28 to 2.39) relative to asymptomatic G2 AEs (OR, 1.45; 95% CrI, 1.12 to 1.89). CONCLUSION Low- and moderate-grade AEs are related to increased odds of increased patient side-effect bother and treatment discontinuation, with symptomatic AEs demonstrating greater magnitude of association than asymptomatic. Our findings suggest that limiting AE capture to grade 3+ misses important contributors to treatment side-effect bother and discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Wake Forest University School of Medicine, Winston-Salem, NC.
- Dana Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Boston, MA.
- Northwestern University Feinberg School of Medicine, Chicago, IL.
- Research Advocacy Network, Chicago, IL.
- Department of Epidemiology and the Center for Statistical Sciences, Brown University School of Public Health, Providence, RI.
- University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.
ORCID-Profile: Nathaniel S O'Connell, Ju-Whei Lee, Edward H Ip, John Devin Peipert, Ilana F Gareen, Ruth C Carlos, Samilia Obeng-Gyasi, Joseph A Sparano, Tait D Shanafelt, David Cella, Lynne I Wagner, Robert Gray
Förderung
- NCI NIH HHS
Zitieren
APA
O'Connell, N. S., Zhao, F., Lee, J. W., Ip, E. H., Peipert, J. D., Graham, N., Smith, M. L., Gareen, I. F., Carlos, R. C., Obeng-Gyasi, S., Sparano, J. A., Shanafelt, T. D., Thomas, M. L., Cella, D., Wagner, L. I., & Gray, R. (2024). Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. Journal of Clinical Oncology, 42(3), 266-272. https://doi.org/10.1200/jco.23.00377
Vancouver
O'Connell NS, Zhao F, Lee JW, Ip EH, Peipert JD, Graham N, et al. Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial. Journal of Clinical Oncology. 2024;42(3):266-272. doi:10.1200/jco.23.00377
BibTeX
@article{OConnell2024,
author = {O'Connell, Nathaniel S and Zhao, Fengmin and Lee, Ju-Whei and Ip, Edward H and Peipert, John Devin and Graham, Noah and Smith, Mary Lou and Gareen, Ilana F and Carlos, Ruth C and Obeng-Gyasi, Samilia and Sparano, Joseph A and Shanafelt, Tait D and Thomas, Mary L and Cella, David and Wagner, Lynne I and Gray, Robert},
title = {Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {3},
pages = {266--272},
doi = {10.1200/jco.23.00377}
}
EUVIMED